Your browser doesn't support javascript.
loading
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Moriyama, B; Obeng, A Owusu; Barbarino, J; Penzak, S R; Henning, S A; Scott, S A; Agúndez, Jag; Wingard, J R; McLeod, H L; Klein, T E; Cross, S J; Caudle, K E; Walsh, T J.
Afiliação
  • Moriyama B; National Institutes of Health Clinical Center Pharmacy Department, Bethesda, Maryland, USA.
  • Obeng AO; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Barbarino J; Department of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.
  • Penzak SR; Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Henning SA; Department of Genetics, Stanford University, Stanford, California, USA.
  • Scott SA; Department of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA.
  • Agúndez J; National Institutes of Health Clinical Center Pharmacy Department, Bethesda, Maryland, USA.
  • Wingard JR; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • McLeod HL; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Klein TE; Department of Pharmacology, University of Extremadura, Cáceres, Spain.
  • Cross SJ; University of Florida College of Medicine, Gainesville, Florida, USA.
  • Caudle KE; DeBartolo Family Personalized Medicine Institute, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida, USA.
  • Walsh TJ; Department of Genetics, Stanford University, Stanford, California, USA.
Clin Pharmacol Ther ; 102(1): 45-51, 2017 07.
Article em En | MEDLINE | ID: mdl-27981572
ABSTRACT
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https//cpicpgx.org/guidelines/ and www.pharmgkb.org).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Taxa de Depuração Metabólica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Técnicas de Genotipagem / Voriconazol / Citocromo P-450 CYP2C19 Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Taxa de Depuração Metabólica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Técnicas de Genotipagem / Voriconazol / Citocromo P-450 CYP2C19 Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos